A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

NCT07082725 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Niemann-Pick Type C Disease

Interventions

DRUG: Nizubaglustat
DRUG: Placebo

Sponsor

Azafaros A.G.